95 related articles for article (PubMed ID: 24791791)
41. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
42. p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Montariello D; Troiano A; Malanga M; Calabrò V; Quesada P
Biochem Pharmacol; 2013 Apr; 85(7):999-1006. PubMed ID: 23376119
[TBL] [Abstract][Full Text] [Related]
43. Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Different Mechanisms.
Kang J; Park JH; Lee HJ; Jo U; Park JK; Seo JH; Kim YH; Kim I; Park KH
Cancer Res Treat; 2016 Apr; 48(2):715-26. PubMed ID: 26511813
[TBL] [Abstract][Full Text] [Related]
44. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway.
Pan H; Zhou W; He W; Liu X; Ding Q; Ling L; Zha X; Wang S
Int J Mol Med; 2012 Aug; 30(2):337-43. PubMed ID: 22580499
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.
Chevanne M; Zampieri M; Caldini R; Rizzo A; Ciccarone F; Catizone A; D'Angelo C; Guastafierro T; Biroccio A; Reale A; Zupi G; Caiafa P
J Cell Physiol; 2010 Feb; 222(2):401-10. PubMed ID: 19890834
[TBL] [Abstract][Full Text] [Related]
46. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel.
Feng LX; Li M; Liu YJ; Yang SM; Zhang N
Int J Mol Sci; 2014 Mar; 15(3):4201-20. PubMed ID: 24619193
[TBL] [Abstract][Full Text] [Related]
47. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells.
Castellanos-Esparza YC; Wu S; Huang L; Buquet C; Shen R; Sanchez-Gonzalez B; García Latorre EA; Boyer O; Varin R; Jiménez-Zamudio LA; Janin A; Vannier JP; Li H; Lu H
Int J Oncol; 2018 Apr; 52(4):1246-1254. PubMed ID: 29436616
[TBL] [Abstract][Full Text] [Related]
48. Anti-Cancer Effects of Sulfasalazine and Vitamin E Succinate in MDA-MB 231 Triple-Negative Breast Cancer Cells.
Wei CW; Yu YL; Lu JY; Hung YT; Liu HC; Yiang GT
Int J Med Sci; 2019; 16(4):494-500. PubMed ID: 31171899
[No Abstract] [Full Text] [Related]
49. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Papeo G; Posteri H; Borghi D; Busel AA; Caprera F; Casale E; Ciomei M; Cirla A; Corti E; D'Anello M; Fasolini M; Forte B; Galvani A; Isacchi A; Khvat A; Krasavin MY; Lupi R; Orsini P; Perego R; Pesenti E; Pezzetta D; Rainoldi S; Riccardi-Sirtori F; Scolaro A; Sola F; Zuccotto F; Felder ER; Donati D; Montagnoli A
J Med Chem; 2015 Sep; 58(17):6875-98. PubMed ID: 26222319
[TBL] [Abstract][Full Text] [Related]
50. The effects of celecoxib on the proliferation and ultrastructural changes of MDA-MB-231 breast cancer cells.
Ma Q; Gao Y; Wei DF; Jiang NH; Ding L; He X; Wei L; Zhang JW
Ultrastruct Pathol; 2018; 42(3):289-294. PubMed ID: 29668331
[TBL] [Abstract][Full Text] [Related]
51. Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
Hongthong K; Nhukeaw T; Temboot P; Dyson PJ; Ratanaphan A
Heliyon; 2021 Aug; 7(8):e07749. PubMed ID: 34430738
[TBL] [Abstract][Full Text] [Related]
52. Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.
McCrudden CM; O'Rourke MG; Cherry KE; Yuen HF; O'Rourke D; Babur M; Telfer BA; Thomas HD; Keane P; Nambirajan T; Hagan C; O'Sullivan JM; Shaw C; Williams KJ; Curtin NJ; Hirst DG; Robson T
PLoS One; 2015; 10(2):e0118187. PubMed ID: 25689628
[TBL] [Abstract][Full Text] [Related]
53. Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer.
Schneider J; Jeon YW; Suh YJ; Lim ST
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269680
[TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line.
Nøhr-Nielsen A; Bagger SO; Brünner N; Stenvang J; Lund TM
Eur J Pharm Sci; 2020 May; 148():105315. PubMed ID: 32201343
[TBL] [Abstract][Full Text] [Related]
55. Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells.
Zhao W; Hu H; Mo Q; Guan Y; Li Y; Du Y; Li L
Int J Clin Exp Pathol; 2019; 12(10):3915-3920. PubMed ID: 31933782
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of amentoflavone metabolites on PARP-1 inhibition and the potentiation on anti-proliferative effects of carboplatin in A549 cells.
Wang B; Hu X; Wang R; Long H; Wang H
Bioorg Med Chem Lett; 2022 Jan; 56():128480. PubMed ID: 34843914
[TBL] [Abstract][Full Text] [Related]
57. Effects of melatonin combined with Cis-platinum or methotrexate on the proliferation of osteosarcoma cell line SaOS-2.
Wang YP; Yang ZP
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2015 Apr; 37(2):215-20. PubMed ID: 25936711
[TBL] [Abstract][Full Text] [Related]
58. In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer.
Paiva KLR; Radicchi MA; Báo SN
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956870
[TBL] [Abstract][Full Text] [Related]
59. [Effects of NVP-BKM120 on the triple-negative breast cancer cell].
Zhang M; Zhou Y; Hu Y; Zhang J
Zhonghua Yi Xue Za Zhi; 2015 Oct; 95(40):3308-12. PubMed ID: 26815355
[TBL] [Abstract][Full Text] [Related]
60. Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells
Yin LL; Wen XM; Lai QH; Li J; Wang XW
Oncol Lett; 2018 May; 15(5):6469-6474. PubMed ID: 29616116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
